PHASE 2 STUDY OF IRINOTECAN AS THE THIRD LINE TREATMENT FOR ADVANCED NON-SMALL CELL LUNG CANCER (NJLCG0703)

被引：0
|
作者：
Watanabe, K. [1 ]
Maemondo, M. [1 ]
Inoue, A. [2 ]
Ishimoto, O. [3 ]
Morikawa, N. [4 ]
Matsubara, N. [1 ]
Sakakibara, T. [2 ]
Fukuhara, T. [2 ]
Sugawara, S. [3 ]
Nukiwa, T. [2 ]
机构：
[1] Miyagi Canc Ctr, Dept Resp Med, Natori, Miyagi 9811293, Japan
[2] Tohoku Univ, Sendai, Miyagi 980, Japan
[3] Sendai Kousei Hosp, Sendai, Miyagi, Japan
[4] Saka Hosp, Shiogama, Japan
来源：
ANNALS OF ONCOLOGY | 2010年 / 21卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：156 / 156
页数：1
相关论文
共 50 条
  • [1] A phase II study of irinotecan as a third- or fourth-line treatment for advanced non-small cell lung cancer: NJLCG0703
    Matsubara, Nobumichi
    Maemondo, Makoto
    Inoue, Akira
    Ishimoto, Osamu
    Watanabe, Kana
    Sakakibara, Tomohiro
    Fukuhara, Tatsuro
    Morikawa, Naoto
    Tanaka, Masashi
    Sugawara, Shunichi
    Nukiwa, Toshihiro
    [J]. RESPIRATORY INVESTIGATION, 2013, 51 (01) : 28 - 34
  • [2] Phase II study of tarceva as third-line treatment in advanced non-small cell lung cancer
    de Castro, Javier
    Pallares, Cinta
    Gurpide, Alfonso
    Cobo, Manuel
    Paz-Ares, Luis
    Gonzalez-Larriba, Jose Luis
    Insa, Amelia
    Domine, Manuel
    Sanchez, Rocio
    Massuti, Bartomeu
    [J]. ANNALS OF ONCOLOGY, 2006, 17 : 236 - 236
  • [3] Front-line treatment of advanced non-small cell lung cancer with irinotecan and docetaxel: A multicentre phase II study
    Ziotopoulos, P
    Androulakis, N
    Mylonaki, E
    Chandrinos, V
    Zachariadis, E
    Boukovinas, I
    Agelidou, A
    Kentepozidis, N
    Ignatiadis, M
    Vossos, A
    Georgoulias, V
    [J]. LUNG CANCER, 2005, 50 (01) : 115 - 122
  • [4] Phase II study of irinotecan and carboplatin for advanced non-small cell lung cancer
    Takeda, K
    Takifuji, N
    Uejima, H
    Yoshimura, N
    Terakawa, K
    Negoro, S
    [J]. LUNG CANCER, 2002, 38 (03) : 303 - 308
  • [5] Phase II trial of temozolomide and irinotecan as second-line treatment for advanced non-small cell lung cancer
    Choong, Nicholas W.
    Mazcer, Ann M.
    Hoffman, Philip C.
    Rudin, Charles M.
    Winegarden, Jerome D., III
    Villano, J. Lee
    Kozloff, Mark
    Wade, James L., III
    Sciortino, David F.
    Szeto, Livia
    Vokes, Everett E.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2006, 1 (03) : 245 - 251
  • [6] Phase I and pharmacologic study of irinotecan and amrubicin in advanced non-small cell lung cancer
    Yanaihara, Tomoko
    Yokoba, Masanori
    Onoda, Sayaka
    Yamamoto, Michiko
    Ryuge, Shinichiro
    Hagiri, Shintaro
    Katagiri, Masato
    Wada, Mayuko
    Mitsufuji, Hisashi
    Kubota, Masaru
    Arai, Susumu
    Kobayashi, Hirosuke
    Yanase, Nobuo
    Abe, Tadashi
    Masuda, Noriyuki
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2007, 59 (04) : 419 - 427
  • [7] Phase II study of irinotecan and ifosfamide in patients with advanced non-small cell lung cancer
    Ichiki, M
    Rikimaru, T
    Gohara, R
    Koga, T
    Kawayama, T
    Matunami, M
    Oshita, Y
    Kamimura, T
    Aizawa, H
    [J]. ONCOLOGY, 2003, 64 (04) : 306 - 311
  • [8] Phase I and pharmacologic study of irinotecan and amrubicin in advanced non-small cell lung cancer
    Tomoko Yanaihara
    Masanori Yokoba
    Sayaka Onoda
    Michiko Yamamoto
    Shinichiro Ryuge
    Shintaro Hagiri
    Masato Katagiri
    Mayuko Wada
    Hisashi Mitsufuji
    Masaru Kubota
    Susumu Arai
    Hirosuke Kobayashi
    Nobuo Yanase
    Tadashi Abe
    Noriyuki Masuda
    [J]. Cancer Chemotherapy and Pharmacology, 2007, 59 : 419 - 427
  • [9] Second and third line treatment in non-small cell lung cancer
    Favaretto, Adolfo
    Pasello, Giulia
    Magro, Cristina
    Schettino, Clorinda
    Gridelli, Cesare
    [J]. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2009, 71 (02) : 117 - 126
  • [10] Front-line treatment of advanced non-small cell lung cancer with Docetaxel and Irinotecan: A multicenter phase II trial
    Ziotopoulos, P.
    Mylonaki, E.
    Boukovinas, J.
    Agelidou, M.
    Chandrinos, V.
    Zachariadis, E.
    Varthalitis, J.
    Ardavanis, A.
    Christopoulou, A.
    Georgoulias, V.
    [J]. ANNALS OF ONCOLOGY, 2004, 15 : 178 - 178
12345